首页>
外国专利>
PHOTOSENSIBILIZER CONTAINING A PHTALOCIANINE DERIVATIVE FOR PHOTODYNAMIC TUMOR THERAPY.
PHOTOSENSIBILIZER CONTAINING A PHTALOCIANINE DERIVATIVE FOR PHOTODYNAMIC TUMOR THERAPY.
展开▼
机译:包含酞菁衍生物的光敏剂,用于光动力肿瘤治疗。
展开▼
页面导航
摘要
著录项
相似文献
摘要
FORMULA COMPOUNDS ARE SUBMITTED (I) THAT ARE USEFULLY EMPLOYED IN PHARMACEUTICAL COMPOSITIONS BOTH MIXED AS IN ASSOCIATION WITH A CARRIER OR A PHARMACOLOGICALLY ACCEPTABLE DILUENT; WHERE M IS A DIAMAGNETIC METAL ATOM OR A DIAMAGNETIC OR SILICON METAL COMPOSITE OR A SILICON COMPOUND OR IS 2H; H IS UNITED TO EACH OF THE TWO NITROGEN ATOMS REPRESENTED AS UNITED TO M (POSITIONS 29 AND 31 SHOWN); R1 TO R25 ARE EQUAL OR DIFFERENT AND ARE SELECTED INDEPENDENTLY BETWEEN RENT C {SUB, 1-20}, ALQUENILO C {SUB, 220}, XOY, (A), X {SP, 2} COOX {SP, 1}, X {SP, 2} CONR1R11 YH; WHERE XYX {SP, 2} IS SELECTED INDEPENDENTLY BETWEEN A CHEMICAL LINK, - (CH {SUB, 2}) {SUB, N} - WHERE N IS A WHOLE BETWEEN 1 AND 20 AND - (CH {SUB, 2} {SUB, A} CH = CH (CH {SUB, 2}) {SUB, B} WHERE A AND B ARE SELECTED INDEPENDENTLY BETWEEN 0-20 YA + B VALID BETWEEN 0 AND 20; X {SP, 1} SELECTED INDEPENDENTLY BETWEEN RENT C {SUB, 1-20}, RENT C {SUB, 2-20} YH, R1 AND R11 SELECTED INDEPENDENTLY BETWEEN H, RENT C {SUB, 1-20}, RENT C {SUB, 2-20 }, - (CH {SUB, 2}) {SUB, N} -; AND IS SELECTED INDEPENDENTLY BETWEEN RENT C {SUB, 1-20}, RENT C {SUB, 220} YH; TAKING INTO ACCOUNT THAT NOT ALL R1- R25 ARE SIMULTANEOUSLY H. THE COMPOUNDS OF FORMULA (I) CAN ALSO BE USED FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR PHOTODYNAMIC THERAPY.
展开▼
机译:提交的配方化合物(I)通常与与载体或药理学上可接受的稀释剂混合使用的药物组合物; M为反磁性金属原子或反磁性或硅金属复合物或硅化合物,或为2H; H代表M代表的两个氮原子(位置29和31所示); R1至R25相等或不同,并且是在租金C {SUB,1-20},ALQUENILO C {SUB,220},XOY,(A),X {SP,2} COOX {SP,1},X之间独立选择的{SP,2} CONR1R11 YH;在化学链接之间独立选择XYX {SP,2}的位置-(CH {SUB,2}){SUB,N}-在N的1和20范围内,并且-(CH {SUB,2} {SUB ,A} CH = CH(CH {SUB,2}){SUB,B}在A和B之间分别选择0-20 YA和B在0和20之间有效; X {SP,1}独立在租用C之间选择{SUB,1-20},租金C {SUB,2-20} YH,H,RENT C {SUB,1-20},RENT C {SUB,2-20}之间独立选择的RH和R11,-(CH {SUB,2}){SUB,N}-;并且在C租区{SUB,1-20},C租区{SUB,220} YH之间独立选择;并考虑到并非所有R1-R25都同时为H。式(I)的化合物也可以用于制备光动力疗法的药物产品。
展开▼